Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.JBIO · Entity 4757 | See Remarks | February 12, 2026 | February 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date February 12, 2026 · Filed February 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 386,113 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 41,250 · Balance 386,113 F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2036-02-11 | Direct | 247,500 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 247,500 · Balance 247,500 F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 19,157 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2029-06-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 43,047 · Balance 0 F2: This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 73,047 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 89,545 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 60,000 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.59 · Expires 2031-06-06 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 21,500 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-11 · Disposition to issuer · Disposed 104,000 · Balance 0 F8: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-11 · Disposition to issuer · Disposed 10,152 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-11 · Disposition to issuer · Disposed 6,802 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-11 · Disposition to issuer · Disposed 16,667 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-08-11 · Disposition to issuer · Disposed 6,667 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F13: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-08-11 · Disposition to issuer · Disposed 26,000 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F14: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-08-11 · Disposition to issuer · Disposed 8,400 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F15: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F7: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F8: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F13: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F14: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F15: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 14, 2026 01:00 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 247,500 | $0.00 Strike: $14.81 | $0.00 |
DisclosureSEC source: 0001193125-26-052053 · ownership.xml · derivative · entry 2 King Andrew James · CIK 0001823187 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,500 Underlying: Common Stock · 247,500 shares Expires 2036-02-11 F2 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 01:00 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantCommon Stock | 41,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-052053 · ownership.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,113 F1 · shares: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 8,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 14 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,400 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F15 · price: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F15 · derivative.exercise_date: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F15 · derivative.expiration_date: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 26,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 13 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F14 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F14 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F14 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 12 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F13 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F13 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F13 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 11 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F12 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F12 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 6,802 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 10 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,802 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F11 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F11 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 10,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 9 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,152 shares Expires not disclosed F9 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F10 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F10 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 104,000 | $14.73 Strike: $25.27 | $1,531,920.00 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 8 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,000 shares Expires 2033-01-30 F8 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | $27.10 Strike: $12.90 | $2,710,000.00 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 7 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-01-30 F7 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,500 | $22.41 Strike: $17.59 | $481,815.00 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 6 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2031-06-06 F6 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | $24.86 Strike: $15.14 | $1,491,600.00 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 5 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2031-02-09 F5 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 89,545 | $25.23 Strike: $14.77 | $2,259,220.35 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 4 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,545 shares Expires 2030-10-05 F4 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 73,047 | $39.58 Strike: $0.42 | $2,891,200.26 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,047 shares Expires 2030-03-18 F3 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 43,047 | $39.65 Strike: $0.35 | $1,706,813.55 |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · derivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,047 shares Expires 2029-06-05 F2 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 19,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045424 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| August 01, 2023 Filed Aug 1, 2023 19:27 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 1,168 | $39.03 | $45,585.87 |
DisclosureSEC source: 0001209191-23-044071 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,157 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| July 29, 2023 Filed Aug 1, 2023 19:27 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044071 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 3,333 shares Expires 2025-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| July 29, 2023 Filed Aug 1, 2023 19:27 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044071 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:43 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-23-023351 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,047 Underlying: Common Stock · 2,500 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:43 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 5,000 | $23.34 | $116,717.50 |
DisclosureSEC source: 0001209191-23-023351 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,992 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.98 to $23.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:43 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 2,500 | $0.35 | $875.00 |
DisclosureSEC source: 0001209191-23-023351 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 16:39 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 6,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009766 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,802 Underlying: Common Stock · 6,803 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 16:39 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 2,392 | $23.75 | $56,806.41 |
DisclosureSEC source: 0001209191-23-009766 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,492 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 16:39 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 6,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-009766 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Unit · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006371 · doc4.xml · derivative · entry 5 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 104,000 | $0.00 Strike: $25.27 | $0.00 |
DisclosureSEC source: 0001209191-23-006371 · doc4.xml · derivative · entry 4 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2033-01-30 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Unirt · Derivative | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006371 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 3,244 | $24.68 | $80,069.06 |
DisclosureSEC source: 0001209191-23-006371 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,081 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-006371 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 19:44 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-23-001434 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,547 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 19:44 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 10,000 | $25.82 | $258,183.00 |
DisclosureSEC source: 0001209191-23-001434 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,992 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.585 to $26.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 19:44 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 7,500 | $0.35 | $2,625.00 |
DisclosureSEC source: 0001209191-23-001434 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 16:32 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 10,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053301 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,152 Underlying: Common Stock · 10,152 shares Expires 2030-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 16:32 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 3,557 | $19.69 | $70,044.44 |
DisclosureSEC source: 0001209191-22-053301 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,492 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 16:32 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 10,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053301 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 17:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-22-044596 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,047 Underlying: Common Stock · 5,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 17:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001209191-22-044596 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 17:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 5,000 | $0.35 | $1,750.00 |
DisclosureSEC source: 0001209191-22-044596 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 16:50 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043899 · doc4.xml · derivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-22-042041 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,047 Underlying: Common Stock · 5,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 5,000 | $18.09 | $90,468.00 |
DisclosureSEC source: 0001209191-22-042041 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $18.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 5,000 | $0.35 | $1,750.00 |
DisclosureSEC source: 0001209191-22-042041 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:34 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-22-024324 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,047 Underlying: Common Stock · 5,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:34 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 5,000 | $15.36 | $76,812.00 |
DisclosureSEC source: 0001209191-22-024324 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:34 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 5,000 | $0.35 | $1,750.00 |
DisclosureSEC source: 0001209191-22-024324 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 17:17 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 2,500 | $13.00 | $32,500.00 |
DisclosureSEC source: 0001209191-22-012315 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 2,498 | $12.74 | $31,827.27 |
DisclosureSEC source: 0001209191-22-009564 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,397 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 17:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-22-008937 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,047 Underlying: Common Stock · 2,500 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 17:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 2,500 | $13.31 | $33,275.00 |
DisclosureSEC source: 0001209191-22-008937 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,094 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.